Elevated Cystatin C Levels Are Associated with Cognitive Impairment and Progression of Parkinson Disease
Elevated Cystatin C Levels Are Associated with Cognitive Impairment and Progression of Parkinson Disease
复制标题
胱抑素 C 水平升高与认知障碍和帕金森病进展相关
DOI：
10.1097/wnn.0000000000000100
复制
发表时间：
2016-09-01
影响因子：
1.4
通讯作者：
Liu, Chun-Feng
中科院分区：
文献类型：
--
作者：
Hu, Wei-Dong;Chen, Jing;Liu, Chun-Feng
目的：探讨帕金森病患者血清胱抑素C（CysC）水平与认知功能障碍及疾病进展的关系。背景：以前的研究报道了神经退行性疾病中CysC水平的改变，但只有少数研究探讨了CysC的作用及其与帕金森病认知功能障碍的关系。方法：检测142例帕金森病患者和146例健康对照者血清CysC、肌酐、尿素和尿酸水平。我们使用Hoehn和Yahr量表评估疾病进展，使用蒙特利尔认知评估（北京版）评估认知功能。结果：帕金森病患者血清CysC水平明显高于正常对照组（P<0.001）。CysC水平与年龄（r=0.494，P<0.001）、性别（r=0.150，P=0.011）、血肌酐水平（r=0.377，P<0.001）显著相关，与尿素、尿酸水平无相关性（P>0.05）。多因素Logistic回归分析显示，CysC水平是帕金森病的独立预测因子（OR =23.143，95%可信区间：5.485-97.648，P<0.001）。在帕金森病组中，较高的CysC水平与更晚期的Hoehn和Yahr分期（r=0.098，P<0.05）和较低的蒙特利尔认知评估评分（r=-0.381，P=0.003）相关。结论：血清CysC水平可预测帕金森病患者的病情严重程度和认知功能障碍。CysC的确切作用仍有待确定。
Objective:We investigated the relationship between serum cystatin C (CysC) levels and cognitive dysfunction and disease progression in patients with Parkinson disease. Background:Previous studies have reported altered CysC levels in neurodegenerative disorders, but only a few studies have explored the role of CysC and its relationship to cognitive dysfunction in Parkinson disease. Methods:We measured serum levels of CysC, creatinine, urea, and uric acid in 142 patients with Parkinson disease and 146 healthy controls. We assessed disease progression using the Hoehn and Yahr scale, and cognitive function using the Montreal Cognitive Assessment (Beijing version). Results:The patients with Parkinson disease had significantly higher CysC levels than the controls (P<0.001). CysC level correlated significantly with age (r=0.494, P<0.001), sex (r=0.150, P=0.011), and serum creatinine level (r=0.377, P<0.001), but not with levels of urea or uric acid (P>0.05). CysC level was a significant independent predictor of Parkinson disease (odds ratio=23.143, 95% confidence interval: 5.485-97.648, P<0.001) in multivariate logistic regression analysis. In the Parkinson disease group, a higher CysC level was associated with a more advanced Hoehn and Yahr stage (r=0.098, P<0.05) and a lower Montreal Cognitive Assessment score (r=−0.381, P=0.003). Conclusions:Serum CysC levels can predict disease severity and cognitive dysfunction in patients with Parkinson disease. The exact role of CysC remains to be determined.